JP2021101720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021101720A5 JP2021101720A5 JP2021053470A JP2021053470A JP2021101720A5 JP 2021101720 A5 JP2021101720 A5 JP 2021101720A5 JP 2021053470 A JP2021053470 A JP 2021053470A JP 2021053470 A JP2021053470 A JP 2021053470A JP 2021101720 A5 JP2021101720 A5 JP 2021101720A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 151
- 239000000427 antigen Substances 0.000 claims description 61
- 102000036639 antigens Human genes 0.000 claims description 61
- 108091007433 antigens Proteins 0.000 claims description 61
- 239000012634 fragment Substances 0.000 claims description 61
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 26
- 108010074864 Factor XI Proteins 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 12
- 102100030563 Coagulation factor XI Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 6
- 108010076282 Factor IX Proteins 0.000 claims description 6
- 108010080805 Factor XIa Proteins 0.000 claims description 6
- 229960004222 factor ix Drugs 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 230000009424 thromboembolic effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 230000004988 N-glycosylation Effects 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 description 13
- 238000007792 addition Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349888P | 2016-06-14 | 2016-06-14 | |
| US62/349,888 | 2016-06-14 | ||
| JP2018565042A JP7022081B2 (ja) | 2016-06-14 | 2017-06-12 | 抗凝固因子ｘｉ抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565042A Division JP7022081B2 (ja) | 2016-06-14 | 2017-06-12 | 抗凝固因子ｘｉ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021101720A JP2021101720A (ja) | 2021-07-15 |
| JP2021101720A5 true JP2021101720A5 (https=) | 2021-08-26 |
| JP7277500B2 JP7277500B2 (ja) | 2023-05-19 |
Family
ID=59078269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565042A Active JP7022081B2 (ja) | 2016-06-14 | 2017-06-12 | 抗凝固因子ｘｉ抗体 |
| JP2021053470A Active JP7277500B2 (ja) | 2016-06-14 | 2021-03-26 | 抗凝固因子ｘｉ抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565042A Active JP7022081B2 (ja) | 2016-06-14 | 2017-06-12 | 抗凝固因子ｘｉ抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10676536B2 (https=) |
| EP (1) | EP3469002A1 (https=) |
| JP (2) | JP7022081B2 (https=) |
| KR (2) | KR102218714B1 (https=) |
| CN (2) | CN109476758B (https=) |
| AR (1) | AR108717A1 (https=) |
| AU (3) | AU2017286432B2 (https=) |
| BR (1) | BR112018075858A2 (https=) |
| CA (2) | CA3025869C (https=) |
| CL (2) | CL2018003565A1 (https=) |
| CO (1) | CO2018013434A2 (https=) |
| CR (1) | CR20180583A (https=) |
| DO (1) | DOP2018000284A (https=) |
| EA (1) | EA201892716A1 (https=) |
| EC (1) | ECSP18091593A (https=) |
| GE (2) | GEP20227382B (https=) |
| IL (2) | IL263272B2 (https=) |
| JO (1) | JOP20180121A1 (https=) |
| MA (1) | MA45234A (https=) |
| MX (2) | MX2018015757A (https=) |
| MY (1) | MY201852A (https=) |
| NI (1) | NI201800134A (https=) |
| PE (1) | PE20190416A1 (https=) |
| PH (1) | PH12018502586A1 (https=) |
| SG (2) | SG11201810763TA (https=) |
| TN (1) | TN2018000417A1 (https=) |
| TW (2) | TWI802193B (https=) |
| UA (1) | UA129793C2 (https=) |
| WO (1) | WO2017218371A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36751A (es) | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| IL263272B2 (en) | 2016-06-14 | 2025-07-01 | Merck Sharp & Dohme | Antibodies to coagulation factor xi |
| IL267538B2 (en) | 2016-12-23 | 2024-05-01 | Novartis Ag | Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient |
| CN110423278B (zh) * | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| EP4177274A4 (en) * | 2020-07-02 | 2024-04-03 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| CA3188566A1 (en) * | 2020-07-03 | 2022-01-06 | Suzhou Alphamab Co., Ltd. | Coagulation factor xi (fxi) binding protein |
| IL304971A (en) | 2021-02-09 | 2023-10-01 | Arxx Therapeutics As | Humanized anti-S100A4 antibody, uses and methods |
| US20250034277A1 (en) * | 2021-11-30 | 2025-01-30 | Suzhou Alphamab Co., Ltd. | Method for preventing and/or treating thromboembolic diseases |
| EP4644426A1 (en) * | 2022-12-30 | 2025-11-05 | Gan & Lee Pharmaceuticals Co., Ltd. | Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof |
| WO2025130748A1 (zh) * | 2023-12-22 | 2025-06-26 | 四川科伦博泰生物医药股份有限公司 | 一种抗凝血因子XI/XIa抗体制剂 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| EP0420937B1 (en) | 1988-06-21 | 1994-11-09 | Genentech, Inc. | Therapeutic compositions for the treatment of myocardial infarction |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH0656382A (ja) | 1992-08-04 | 1994-03-01 | Kawasaki Steel Corp | コークス乾式消火装置のバケット巻上機の吊ビーム装置 |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| BRPI0108923B8 (pt) | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| EP1532175B1 (en) | 2002-03-22 | 2012-10-17 | Aprogen, Inc. | Humanized antibody and process for preparing the same |
| CN102408483B (zh) | 2003-07-15 | 2016-06-08 | 安姆根有限公司 | 作为选择性ngf途径抑制剂的人抗ngf中和抗体 |
| SG158150A1 (en) | 2004-12-21 | 2010-01-29 | Centocor Inc | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| US8383118B2 (en) | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| US7960518B2 (en) | 2006-06-06 | 2011-06-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
| TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| CA2680741A1 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| TW200927761A (en) | 2007-09-26 | 2009-07-01 | U3 Pharma Ag | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| PT3002298T (pt) * | 2007-11-21 | 2019-11-20 | Univ Oregon Health & Science | Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos |
| AU2016203944A1 (en) | 2007-11-21 | 2016-07-07 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| WO2009154461A1 (en) | 2008-06-19 | 2009-12-23 | Prothix Bv | Use of anti-factors xi antibodies for prevention of thrombus formation |
| WO2010014854A2 (en) | 2008-07-31 | 2010-02-04 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| PE20110808A1 (es) | 2008-10-31 | 2011-10-31 | Janssen Biotech Inc | Anticuerpos contra el receptor 3 de tipo toll |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8388959B2 (en) | 2008-12-18 | 2013-03-05 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| WO2010072740A2 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF |
| EP2408814B1 (en) | 2009-03-20 | 2018-11-21 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| US8722860B2 (en) | 2009-04-16 | 2014-05-13 | Abbvie Biotherapeutics Inc. | Anti-TNF-α antibodies and their uses |
| US8492119B2 (en) | 2009-04-27 | 2013-07-23 | Kyowa Hakko Kirin Co., Ltd | Antibody to human IL-3 receptor alpha chain |
| CA2777226A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| US9045536B2 (en) | 2009-12-23 | 2015-06-02 | Merck Sharp & Dohme Corp. | Cell line 3M |
| EP2532151A2 (en) * | 2010-02-03 | 2012-12-12 | Trilogy IP Holdings, Inc. | Mobile communication plan offerings |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| AU2011286407A1 (en) | 2010-08-06 | 2013-02-21 | Amgen | Use of HER3 binding agents in prostate treatment |
| SG10201509499RA (en) | 2010-11-19 | 2015-12-30 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
| CA2823776A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| KR20140033029A (ko) | 2011-04-01 | 2014-03-17 | 메모리얼 슬로안-케터링 캔서 센터 | 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체 |
| PL2718322T3 (pl) | 2011-06-06 | 2019-07-31 | Novo Nordisk A/S | Lecznicze przeciwciała |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| EP2650310B1 (en) | 2012-04-13 | 2016-06-08 | Rottapharm Biotech S.r.l. | Anti-ADAMTS-5 antibody, derivatives and uses thereof |
| EP2847228B1 (en) | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| WO2013173255A2 (en) | 2012-05-17 | 2013-11-21 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind egfr |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| AU2014331118B2 (en) | 2013-10-01 | 2019-07-25 | Medimmune Limited | Methods of treating and diagnosing alpha-V-beta-6 overexpressing cancer |
| WO2015141826A1 (ja) | 2014-03-20 | 2015-09-24 | 国立感染症研究所長が代表する日本国 | Ｃ型肝炎ウイルスに対する感染阻害活性を有する抗体 |
| KR101753553B1 (ko) | 2014-06-03 | 2017-07-03 | 엑스바이오테크, 인크. | 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법 |
| EP3177322A4 (en) | 2014-08-08 | 2018-07-18 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| CN107708733B (zh) | 2015-04-07 | 2022-11-15 | 艾利妥 | 抗分拣蛋白抗体和其使用方法 |
| JP7497953B2 (ja) | 2015-06-12 | 2024-06-11 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| UY36751A (es) | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| WO2017015619A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| TWI736575B (zh) | 2016-01-22 | 2021-08-21 | 美商默沙東藥廠 | 抗凝固因子ｘｉ抗體 |
| IL263272B2 (en) | 2016-06-14 | 2025-07-01 | Merck Sharp & Dohme | Antibodies to coagulation factor xi |
| MX2019003077A (es) | 2016-09-20 | 2020-02-05 | Bayer Pharma AG | Anticuerpos novedosos contra el factor xi y sus usos. |
-
2017
- 2017-06-12 IL IL263272A patent/IL263272B2/en unknown
- 2017-06-12 CA CA3025869A patent/CA3025869C/en active Active
- 2017-06-12 SG SG11201810763TA patent/SG11201810763TA/en unknown
- 2017-06-12 CN CN201780037421.3A patent/CN109476758B/zh active Active
- 2017-06-12 KR KR1020197001266A patent/KR102218714B1/ko active Active
- 2017-06-12 JP JP2018565042A patent/JP7022081B2/ja active Active
- 2017-06-12 TN TNP/2018/000417A patent/TN2018000417A1/en unknown
- 2017-06-12 SG SG10202103120UA patent/SG10202103120UA/en unknown
- 2017-06-12 EA EA201892716A patent/EA201892716A1/ru unknown
- 2017-06-12 PE PE2018003203A patent/PE20190416A1/es unknown
- 2017-06-12 CN CN202310501882.9A patent/CN116425879A/zh active Pending
- 2017-06-12 AR ARP170101603A patent/AR108717A1/es unknown
- 2017-06-12 EP EP17731444.0A patent/EP3469002A1/en active Pending
- 2017-06-12 IL IL315266A patent/IL315266A/en unknown
- 2017-06-12 GE GEAP201714983A patent/GEP20227382B/en unknown
- 2017-06-12 KR KR1020217004608A patent/KR102379580B1/ko active Active
- 2017-06-12 GE GEAP202114983A patent/GEAP202114983A/en unknown
- 2017-06-12 WO PCT/US2017/036940 patent/WO2017218371A1/en not_active Ceased
- 2017-06-12 AU AU2017286432A patent/AU2017286432B2/en active Active
- 2017-06-12 BR BR112018075858-2A patent/BR112018075858A2/pt active Search and Examination
- 2017-06-12 UA UAA201900311A patent/UA129793C2/uk unknown
- 2017-06-12 MY MYPI2018002406A patent/MY201852A/en unknown
- 2017-06-12 CA CA3172367A patent/CA3172367A1/en active Pending
- 2017-06-12 TW TW110149482A patent/TWI802193B/zh active
- 2017-06-12 US US15/619,620 patent/US10676536B2/en active Active
- 2017-06-12 MX MX2018015757A patent/MX2018015757A/es unknown
- 2017-06-12 CR CR20180583A patent/CR20180583A/es unknown
- 2017-06-12 MA MA045234A patent/MA45234A/fr unknown
- 2017-06-12 TW TW106119391A patent/TWI752964B/zh active
- 2017-06-16 JO JOP/2018/0121A patent/JOP20180121A1/ar unknown
-
2018
- 2018-12-06 PH PH12018502586A patent/PH12018502586A1/en unknown
- 2018-12-10 NI NI201800134A patent/NI201800134A/es unknown
- 2018-12-11 CL CL2018003565A patent/CL2018003565A1/es unknown
- 2018-12-11 EC ECSENADI201891593A patent/ECSP18091593A/es unknown
- 2018-12-12 CO CONC2018/0013434A patent/CO2018013434A2/es unknown
- 2018-12-13 DO DO2018000284A patent/DOP2018000284A/es unknown
- 2018-12-14 MX MX2023012740A patent/MX2023012740A/es unknown
-
2020
- 2020-05-01 US US16/864,570 patent/US11512142B2/en active Active
- 2020-05-01 US US16/864,559 patent/US11661460B2/en active Active
- 2020-05-01 US US16/864,583 patent/US11479615B2/en active Active
- 2020-05-01 US US16/864,577 patent/US11485794B2/en active Active
- 2020-07-30 AU AU2020210233A patent/AU2020210233B2/en active Active
-
2021
- 2021-03-26 JP JP2021053470A patent/JP7277500B2/ja active Active
-
2023
- 2023-04-18 US US18/302,033 patent/US12275800B2/en active Active
-
2024
- 2024-02-06 CL CL2024000367A patent/CL2024000367A1/es unknown
- 2024-02-20 AU AU2024201084A patent/AU2024201084A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021101720A5 (https=) | ||
| JP6944509B2 (ja) | Ｉｌ−１８結合分子 | |
| JP2025016349A5 (https=) | ||
| US20220289858A1 (en) | Anti-cd40 antibodies and uses thereof | |
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| AU2008243049B2 (en) | Novel compounds | |
| AU2011289629B2 (en) | Anti-N3pGlu amyloid beta peptide antibodies and uses thereof | |
| CA2914170C (en) | Interleukin-13 binding proteins | |
| RU2429245C2 (ru) | Иммуноглобулины | |
| JP2022031635A5 (https=) | ||
| IL315266A (en) | Anti-coagulation factor xi antibodies | |
| TWI699376B (zh) | 抗cd40抗體、其抗原結合片段及其醫藥用途 | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2007530068A5 (https=) | ||
| RU2007132020A (ru) | Партнеры специфического связывания с ngf | |
| EA039946B1 (ru) | Антитела-антагонисты к интерферону альфа и интерферону омега | |
| JP2008527989A5 (https=) | ||
| JP2021534797A5 (https=) | ||
| US20110223176A1 (en) | Basigin binding proteins | |
| JP7060906B2 (ja) | 抗ｉｌ－５抗体 | |
| AU2016404449B2 (en) | Trispecific antibodies against IL-17A, IL-17F and another proinflammatory molecule | |
| WO2022026775A1 (en) | Compositions and methods for targeting coronavirus | |
| AU2014233615B2 (en) | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof | |
| RU2022115671A (ru) | Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с BCMA, и его применение |